A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ administration & dosage
Carcinoma, Neuroendocrine
/ diagnosis
Carcinoma, Small Cell
/ diagnosis
Chemoradiotherapy
/ adverse effects
Cisplatin
/ administration & dosage
Combined Modality Therapy
/ methods
Esophageal Neoplasms
/ pathology
Etoposide
/ administration & dosage
Febrile Neutropenia
/ chemically induced
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
/ methods
Radiation Dosage
Retrospective Studies
Safety
Survival Rate
/ trends
Thrombocytopenia
/ chemically induced
Treatment Outcome
Definitive chemoradiotherapy
Neuroendocrine carcinoma
Resectable esophageal cancer
Small cell carcinoma
Journal
Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
24
04
2019
accepted:
10
07
2019
pubmed:
20
7
2019
medline:
15
7
2021
entrez:
20
7
2019
Statut:
ppublish
Résumé
Standard treatment for resectable small cell neuroendocrine carcinoma of the esophagus (SCNEC-E) remains to be established. We retrospectively studied 7 consecutive patients with resectable SCNEC-E who received definitive chemoradiotherapy (dCRT) to evaluate the safety and efficacy. Treatment consisted of two courses of chemotherapy with cisplatin (80 mg/m The clinical stage was IA in 1 patient, IB in 2 patients, IIA in 3 patients, and IIB in 1 patient. Definitive CRT was completed in all patients. The median overall treatment time of radiotherapy was 44 days. The chemotherapy regimen included in dCRT was cisplatin and etoposide in 3 patients and carboplatin and etoposide in 4 patients. Acute adverse events of grade 3 or 4 were neutropenia 100%, thrombocytopenia 43%, febrile neutropenia 43%, and nausea 14%. There were no late grade 3 or 4 adverse events. The median survival time was 32 months. The complete response rate was 100%. The recurrence rate was 43%. The median survival of the 4 patients without recurrence was 56 months. Definitive CRT with cisplatin and etoposide or carboplatin and etoposide is a feasible treatment for the resectable SCNEC-E, and long-term survival can be achieved in some patients.
Sections du résumé
BACKGROUND
Standard treatment for resectable small cell neuroendocrine carcinoma of the esophagus (SCNEC-E) remains to be established.
METHODS
We retrospectively studied 7 consecutive patients with resectable SCNEC-E who received definitive chemoradiotherapy (dCRT) to evaluate the safety and efficacy. Treatment consisted of two courses of chemotherapy with cisplatin (80 mg/m
RESULTS
The clinical stage was IA in 1 patient, IB in 2 patients, IIA in 3 patients, and IIB in 1 patient. Definitive CRT was completed in all patients. The median overall treatment time of radiotherapy was 44 days. The chemotherapy regimen included in dCRT was cisplatin and etoposide in 3 patients and carboplatin and etoposide in 4 patients. Acute adverse events of grade 3 or 4 were neutropenia 100%, thrombocytopenia 43%, febrile neutropenia 43%, and nausea 14%. There were no late grade 3 or 4 adverse events. The median survival time was 32 months. The complete response rate was 100%. The recurrence rate was 43%. The median survival of the 4 patients without recurrence was 56 months.
CONCLUSIONS
Definitive CRT with cisplatin and etoposide or carboplatin and etoposide is a feasible treatment for the resectable SCNEC-E, and long-term survival can be achieved in some patients.
Identifiants
pubmed: 31321580
doi: 10.1007/s10388-019-00686-9
pii: 10.1007/s10388-019-00686-9
doi:
Substances chimiques
Etoposide
6PLQ3CP4P3
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-140Références
Dis Esophagus. 2017 Feb 1;30(2):1-5
pubmed: 27860114
Radiother Oncol. 2013 Mar;106(3):317-22
pubmed: 23498325
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950
J Thorac Oncol. 2008 Dec;3(12):1460-5
pubmed: 19057273
J Gastroenterol. 2007 Dec;42(12):932-8
pubmed: 18085349
Dis Esophagus. 2009;22(2):113-8
pubmed: 18847450
Dis Esophagus. 2013 Sep-Oct;26(7):696-702
pubmed: 23317069
Cancer. 2000 Jan 15;88(2):262-7
pubmed: 10640955
Chest. 1995 Jan;107(1):179-81
pubmed: 7813272
N Engl J Med. 1992 Dec 3;327(23):1618-24
pubmed: 1331787
J Thorac Cardiovasc Surg. 1995 Feb;109(2):284-8
pubmed: 7531797
Am J Clin Oncol. 2000 Oct;23(5):455-9
pubmed: 11039503
Cancer. 1997 Oct 15;80(8):1366-72
pubmed: 9338459
Br J Cancer. 2007 Mar 12;96(5):708-11
pubmed: 17299393
Ann Thorac Surg. 2002 Dec;74(6):1924-7
pubmed: 12643374
Clin Cancer Res. 2005 Aug 1;11(15):5534-8
pubmed: 16061870
Cancer. 1989 Oct 1;64(7):1531-3
pubmed: 2550125
Dis Esophagus. 2010 Feb;23(2):153-9
pubmed: 19515193
Esophagus. 2017;14(1):1-36
pubmed: 28111535
Am J Clin Oncol. 2002 Aug;25(4):404-7
pubmed: 12151974
Thorac Cardiovasc Surg. 1986 Apr;34(2):71-6
pubmed: 2424132
J Clin Oncol. 1996 Mar;14(3):806-13
pubmed: 8622028
Ann Thorac Surg. 2011 Feb;91(2):373-8
pubmed: 21256272
J Clin Gastroenterol. 1991 Apr;13(2):135-41
pubmed: 1851772
Dis Esophagus. 2011 May;24(4):258-64
pubmed: 21073624
Dis Esophagus. 2010 Aug;23(6):502-5
pubmed: 20113319
Int J Clin Oncol. 2012 Dec;17(6):610-5
pubmed: 22041926
J Clin Oncol. 2006 Nov 20;24(33):5247-52
pubmed: 17114657
Ann Surg Oncol. 2013 Dec;20(13):4239-44
pubmed: 23943025
J Surg Oncol. 1997 Feb;64(2):130-4
pubmed: 9047250